13 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $106M | $83M | 0.0% | -59.1% | -$2M | $62M | $62M |
| 2024 | $24M | -$106M | 0.0% | -368.5% | -$70M | $60M | $34M |
| 2023 | $27M | -$46M | 89.3% | -180.6% | -$34M | $5M | $43M |
| 2022 | $10M | -$27M | 97.8% | -418.9% | -$19M | — | $65M |
| 2021 | $29M | -$9M | 92.8% | 27.0% | $10M | — | $112M |
| 2020 | $13M | -$13M | 0.0% | -42.2% | -$2M | $68M | $4M |
| 2019 | $13M | -$25M | 0.0% | -158.4% | -$24M | $77M | $3M |
| 2018 | $0 | -$56M | — | — | -$54M | $81M | $18M |
| 2017 | — | -$43M | — | — | -$33M | $93M | $11M |
| 2016 | — | -$17M | — | — | -$30M | — | $17M |
| 2015 | — | -$55M | — | — | -$20M | — | $32M |
| 2014 | — | -$24M | — | — | — | — | $10M |
| 2013 | — | -$5M | — | — | — | — | $2M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $36M | $38M | 0.0% | 144.0% | $6M | $0 | $96M |
| Dec '25 | $34M | $12M | 0.0% | 27.3% | $6M | $62M | $62M |
| Sep '25 | $26M | -$544000 | 0.0% | 15.9% | $4M | $61M | $54M |
| Jun '25 | $26M | $75M | 0.0% | -274.5% | -$4M | $61M | $48M |
| Mar '25 | $20M | -$3M | 0.0% | -26.3% | -$8M | $60M | $37M |
| Dec '24 | $12M | -$36M | 0.0% | -128.0% | -$16M | $60M | $34M |
| Sep '24 | $4M | -$33M | 0.0% | -739.0% | -$18M | $59M | $54M |
| Jun '24 | $4M | -$20M | 0.0% | -534.8% | -$19M | $58M | $39M |
| Mar '24 | $3M | -$17M | 0.0% | -598.1% | -$16M | — | $43M |
| Dec '23 | $13M | -$20M | 84.5% | -117.3% | -$16M | $5M | $43M |
| Sep '23 | $3M | -$10M | 95.0% | -530.7% | -$5M | — | $43M |
| Jun '23 | $8M | -$3M | 92.0% | -73.8% | -$9M | — | $66M |
| Mar '23 | $3M | -$13M | 96.1% | -404.0% | -$4M | — | $40M |
| Dec '22 | $2M | $6M | 98.9% | -460.6% | -$4M | — | $65M |
| Sep '22 | $3M | -$7M | 95.1% | -230.5% | -$7M | — | $70M |
| Jun '22 | $1M | -$24M | 96.1% | -1905.2% | -$4M | — | $77M |
| Mar '22 | $4M | -$2M | 99.8% | -46.9% | -$4M | — | $100M |
| Dec '21 | $3M | -$3M | 97.7% | -110.1% | -$865000 | — | $112M |
| Sep '21 | $2M | -$2M | 100.0% | -113.1% | -$3M | — | $132M |
| Jun '21 | $12M | $6M | 91.7% | 48.7% | $17M | — | $132M |
How the market has priced ZVRA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Zevra Therapeutics, Inc.'s revenue has grown 51.6% per year. These are computed facts, not advice.
As of FY2025, Zevra Therapeutics, Inc. reported $62M of total debt against $62M of cash; operating income covered interest expense -7.9×.
In FY2025, gross margin was —, operating margin -59.1%, and net margin 78.2%.
As of Jun '26, Zevra Therapeutics, Inc. traded at a price-to-earnings ratio of about 9.4× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.